No products in the cart.
Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-920
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Moxetumomab Pasudotox biosimilar, Fusion Protein, Moxetumomab-Anti-CD22 Antibody: Anti-SIGLEC-2/SIGLEC2 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A |
|---|---|
| INN Name | moxetumomab pasudotox |
| Target | CD22 |
| Format | Fusion Protein |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | Fv – disulfide stabilized |
| VD LC | Fv – disulfide stabilized |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | MedImmune (Gaithersburg MD USA) / AstraZeneca (London UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Cambridge Antibody Technology (CAT) human antibody phage display library |
| Previous Name | NA |
| Gm Offical Target Name | CD22 |
| Package |
Previous slide
Next slide
